MedTrace Logo

Breast Cancer RElapsed in Patients Treated With Adjuvant CDK4/6 Inhibitors:

NCT07180693 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 750

Last updated 2026-05-07

No results posted yet for this study

Summary

This is a multicenter observational study with both retrospective and prospective phase, designed to evaluate the clinico-pathologic characteristics and outcomes of patients with HR+/HER2- EBC at high risk of recurrence treated with ribociclib or abemaciclib in combination with ET in the adjuvant setting.

Conditions

  • Adjuvant Therapy
  • CDK4/6 Inhibitor

Sponsors & Collaborators

  • European Institute of Oncology

    lead OTHER

Principal Investigators

  • Nadia Bianco, MD · European Institute of Oncology

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-29
Primary Completion
2028-08-01
Completion
2030-08-01

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07180693 on ClinicalTrials.gov